Lakewood-Amedex Biotherapeutics Inc.

Lakewood-Amedex Biotherapeutics Inc. announced a 1-for-10 reverse stock split of its common stock, effective June 19, 2026. The company's shares will begin trading on a split-adjusted basis on Nasdaq on June 22, 2026. This action will reduce the number of outstanding shares and proportionately adjust authorized shares and equity awards.

Lakewood-Amedex Biotherapeutics Inc. reported a net loss of $923,291 for Q1 2026, an increase from $539,617 in Q1 2025, and ended the quarter with only $11,709 in cash, raising substantial doubt about its ability to continue as a going concern. Subsequent to the quarter, the company completed a $7.5 million Series C Convertible Preferred Stock offering and listed on the Nasdaq Capital Market. These actions led to the automatic conversion of $1.5 million in convertible notes and all Series A and B preferred stock into common stock, including $10.6 million in Series B dividends. While these capital actions improved liquidity through Q4 2026, additional funding will be required thereafter, and the going concern doubt persists.

Lakewood-Amedex Biotherapeutics Inc. filed an S-1 registration statement for the resale of 9,647,726 shares of common stock by selling stockholders. This includes 9,375,000 shares convertible from Series C Preferred Stock issued in a January 2026 private placement and 272,726 shares issued for advisory services. The proceeds from the Series C financing are earmarked to fund the upcoming Phase 2a clinical trial for its lead product, Nu-3 gel, targeting mildly infected diabetic foot ulcers. The company, an emerging growth and smaller reporting company, has its common stock trading on Nasdaq under "LABT".

Lakewood-Amedex Biotherapeutics Inc. (LABT) announced the appointment of Dr. Joseph Tucker to its Board of Directors, effective April 24, 2026. Dr. Tucker, currently CEO of Enveric Biosciences Inc., brings over two decades of leadership experience in public and private biotechnology companies, including expertise in capital markets and drug development. This strategic appointment aims to strengthen LABT's governance and strategic capabilities following its recent Nasdaq direct listing, as the company advances its growth strategy and its Bisphosphocin® class antimicrobials.